3. Comparison of median survival: platinum vs. non‐platinum‐containing regimens.
| Study | Platinum containing | Non‐platinum containing | ||||
| n | Median OS (months) |
Median PFS (months) |
n | Median OS (months) |
Median PFS (months) |
|
|
Bezwoda 1986 H vs. CMeth |
37 | 11 (CMeth) | nr | 13 | 4 (H) | nr |
|
Long 2005/Long 2006 C vs. CT vs. MVAC |
146 147 |
6.5 (C) 9.4 (CT) |
2.9 (C) 4.6 (CT) |
63 | 9.4 (MVAC) | 4.4 |
|
Pfeiffer 1998 Carbo vs. Ten |
12 | 9.3 (Carbo) | 4.6 | 14 | 9.6 (Ten) | 4.0 |
C: cisplatin; Carbo: carboplatin; CMeth: cisplatin/methotrexate; CT: cisplatin/topotecan; H: hydroxyurea; MVAC: methotrexate/vinblastine/doxorubicin/cisplatin; nr: not reported; OS: overall survival; PFS: progression‐free survival; Ten: teniposide.